Preemptive Pharmacogenomics Testing Among Geriatric Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-28

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Preemptive Pharmacogenetics in Underserved Patients

NCT05141019

Use of Prescription Medications Pharmacogenetic Testing

ACTIVE_NOT_RECRUITING NA

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

NCT02081872

Genetics of Drug Metabolism

UNKNOWN

Pharmacogenomic Testing Of the Elderly To Reduce Morbidity

NCT02095769

Genetics of Drug Metabolism

UNKNOWN

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

NCT03748355

Psychiatric Disorder

COMPLETED NA

Pharmacogenomics to Improve Supportive Care Symptoms.

NCT06856122

Palliative Care Supportive Care

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pharmacogenomics is the study of how a patient's unique DNA may interact with medications that the patient currently takes or may take in the future. DNA may change how a patient reacts to a medication, such as changing how well it works or the side effects. Knowing a patient's DNA profile may help healthcare professionals select the best medication treatment plan to use. This could include selecting the best medication to give or the medication strength that will work best for the patient. Currently, there is no standard that helps healthcare professionals decide to order a pharmacogenomics test that includes multiple genes. The investigators of this study think that having these DNA results in the medical record for participants who are at least 65 years old and are taking 5 or more medications will result in better health since healthcare professionals may use these results for treatment planning. Knowing if this is true will help healthcare professionals decide if ordering this test will improve patient health.

This study seeks to recruit participants for a pharmacogenomic study who visit at Geisinger 65 Forward locations. Patients who meet the study requirements and consent to be enrolled in this study will be randomly put into a group that receives this pharmacogenomics test or a group that does not receive it. There is a 50% chance of being put in the group that receives this pharmacogenomics test. The investigators will follow all patients enrolled in this study as they visit with their healthcare providers in the future. Geisinger healthcare professionals will have access to the results of this test in the medical record.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polypharmacy Pharmacogenomic Testing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

A multigene pharmacogenomics test will not be ordered for patients in this study arm, as is the standard of care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Pharmacogenomics Testing

Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.

Group Type EXPERIMENTAL

Multigene pharmacogenomics test

Intervention Type GENETIC

This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multigene pharmacogenomics test

This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Follows at a Geisinger 65 Forward clinic location
* Active prescriptions for 5 or more medications

Exclusion Criteria

* Liver transplantation
* Allogenic hematopoetic stem cell transplantation
* Previously enrolled in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No